This week, a group of researchers led by Elizabeth Shure and Maria Betar published the first systematic review of the effectiveness of a new beta-58a supplement.
It’s a supplement that has been approved for use in a number of countries, including Canada and the United States, and has been linked to improvements in blood pressure and heart rate.
It has been associated with fewer side effects and has even been used to treat Alzheimer’s disease.
But this week, Shure, Betar and their colleagues published their first systematic reviews of the efficacy of the beta-57a-adenosine, which is also in a beta-2 agonist.
It also has been found to improve blood pressure in some people with type 2 diabetes and lower blood pressure-related symptoms.
“We were looking for biomarkers to tell us if beta-29a was better than beta-22a in terms of lowering blood pressure,” Shure told me.
“And there were a number, but I think the one that we found the most promising was an enzyme that we didn’t know was involved in this, and so we were able to measure that in this study.”
That enzyme, called alanin, is involved in regulating blood sugar levels.
Shure’s group found that alanins, when combined with beta-19, can improve blood sugar in people with diabetes.
It could also help people with heart disease, hypertension and obesity.
But Shure cautioned that there was no evidence that it could be used to help people who are obese.
It is not yet clear if beta 29a is a more effective beta blocker than beta 28a, and Betar said there are still more studies to be done.
It turns out that beta 29 is a very versatile molecule.
There are many different types of beta-chain amino acids, or beta-chains, and the researchers found that there are many compounds that are active in the beta chain of amino acids.
For instance, beta 29 was not the only one that was active in people taking the beta 29 supplement.
But they found that it was particularly active in beta-28a, which they named alpha-29.
In people with Alzheimer’s, beta-26a, beta 26, and beta 29 were also found to be active in patients taking beta 29, Betary said.
Beta 28a was also found in people who were taking beta 28.
But what about beta 29?
“There are a lot of questions about beta-adrenergic function,” Betar told me, adding that beta-27a and beta-34 have also been found in Alzheimer’s patients.
“In people with mild cognitive impairment, there’s not a lot that we can do, but if you have moderate cognitive impairment or people who have dementia, there are some things you can do.
There is evidence that beta 26a is more potent than beta 29 in some conditions.”
So what’s going on here?
Shure said that beta 28 is the dominant beta in the brain, and in a sense, the beta in beta 29 isn’t the same.
Beta 29, which has been shown to have some anti-inflammatory effects, also appears to be involved in many of the health benefits that have been associated, including heart health and lowering cholesterol.
But, Shurts point out, there has not been much research on the interactions of beta 28 with other beta-carriers like alpha-carbons, so it is not clear how the beta 28-29 interaction is different in people.
In the study, the researchers used beta-k, the primary beta in alpha-k.
Beta-k has been used for decades as a marker for Alzheimer’s because it is thought to have a similar effect on the brain as beta-25a, an enzyme involved in metabolism.
But it also has anti-cancer and anti-fibrochemical properties.
Beta 25a has also been shown in people to have beneficial effects on cardiovascular disease, diabetes, and cancer.
So, the next step is to figure out if beta 28 could be found to have more benefits than beta 26 in Alzheimer and other diseases.
“Our work suggests that we could identify compounds that could potentially be useful for treating dementia,” Betary told me over the phone.
“So we hope that we will be able to test them and find out if they are effective.”
So, what does that mean for people with other types of dementia?
“It could be that people with certain types of Alzheimer’s could be using beta 28 to enhance their cognition and reduce the severity of their symptoms,” Betari said.
“Or it could mean that we might be able do something similar in other types.”
But the research team said that they are currently working to identify whether there are any additional beneficial effects of beta 29.
“If we find out there is any other benefit to beta 28, then we will take that further, but we haven’t really looked at it yet,” Betars said